Eli Lilly and Co.

UPDATE: Pipeline challenges force Lilly restructuring moves

September 14, 2009
J.K. Wall
Since John Lechleiter was named CEO 18 months ago, he's bet that Eli Lilly and Co. could face down its looming patent challenges by launching innovative new medicines. Today's announcement of 5,500 job cuts by the end of 2011 and a restructuring of the company's business units ups the ante on that bet, while indicating that it isn't working yet.
More

Lilly reorganization to cut 5,500 positions over 2 years

September 14, 2009
J.K. Wall
Eli Lilly and Co. will cut 5,500 jobs by the end of 2011 as it tries to cut $1 billion in expenses before it loses revenue from its bestselling drug, Zyprexa. Lilly CEO John Lechleiter said he did not know how many of those cuts would occur in central Indiana. But with 13,600 employees working in the Indianapolis area, he acknowledged the largest chunk of reductions likely would come here.
More

Local health care industry tries to capitalize on migraine headaches

September 12, 2009
J.K. Wall
Migraines cost American employers $20 billion a year in decreased worker productivity. Such a frequent and uncured disease stands as a huge business opportunity for the health care industry, including locally based pharmaceutical giant Eli Lilly and Co.
More

Study weakens Lilly's fight against price controls

September 12, 2009
 IBJ Staff
Eli Lilly and Co. and its peers might be back in Congress’ sights as lawmakers hunt for more ways to cut health care costs. A new study in the influential Health Affairs journal concludes that European drugmakers operating in markets with pharmaceutical price controls have produced proportionally more innovations than their U.S. counterparts.
More

Lilly paid doctors to prescribe Zyprexa, notes say

September 8, 2009
 IBJ Staff
Eli Lilly and Co. paid doctors in South Carolina for participating in a speakers' program in exchange for prescribing the antipsychotic Zyprexa, according to notes by Lilly sales representatives reviewed by Bloomberg News.
More

Lilly drops osteoporosis pipeline drug

August 18, 2009
J.K. Wall
Eli Lilly and Co. pulled the plug on yet another drug in its pipeline that was in the late stages of testing, further complicating the company’s attempts to find revenue before losing patent protection on its bestseller.
More

Lilly pays $224,000 to area doctors

August 17, 2009
 IBJ Staff
It’s no secret that Eli Lilly and Co. is the biggest private employer in the Indianapolis area. But Lilly also supplemented the incomes of a few dozen local doctors — to the tune of more than $224,000 in just the first quarter.
More

Glut of downtown office space grows

August 17, 2009
Cory Schouten
Safeco is leaving a five-building complex on North Meridian Street, and Eli Lilly and Co. has offered for lease its entire four-building Faris campus.

More

Abatement approval paves way for Covance jobs

August 12, 2009
Scott Olson
The Hancock County Council this morning unanimously approved a tax-incentive agreement that should lead Covance Inc. to add 315 jobs at its Greenfield Laboratories.
More

Lilly reorganizes venture capital unitRestricted Content

August 10, 2009
Peter Schnitzler
Eli Lilly and Co. has reorganized its venture capital division and simultaneously poured in an additional $25 million.More

Lilly offering buyouts to 4,000 sales reps

August 4, 2009
Indianapolis-based Eli Lilly and Co. today said it is offering buyouts to its U.S. sales force, with hopes of trimming about 300 sales representatives before a sales restructuring set to begin in January, Reuters reported.
More

Lilly software spinoff Maaguzi sells for $11 millionRestricted Content

August 3, 2009
Chris O'Malley
Investors in a company built around clinical research software bought from Eli Lilly and Co. have found their exit, though it’s far from the lucrative payoff they’d once imagined.
More

Lilly's Effient launch just one of its many challengesRestricted Content

August 3, 2009
Greg Andrews
Eli Lilly and Co. has blasted past analysts’ earnings projections for two straight quarters. But if Lilly officials take that as a sign they can breathe easier, they need only flip through a stack of Wall Street research reports on the company.
More

Eli Lilly CEO, wife give United Way $1M gift

July 28, 2009
Kathleen McLaughlin
Eli Lilly and Co. CEO John Lechleiter and his wife, Sarah, have pledged to give the United Way of Central Indiana a total of $1 million over the next four years as a “challenge to CEOs and other community leaders to step up their giving.”
More

Eli Lilly CEO, wife give United Way $1M gift

July 28, 2009
Kathleen McLaughlin
Eli Lilly and Co. CEO John Lechleiter and his wife, Sarah, have pledged to give the United Way of Central Indiana a total of $1 million over the next four years as a "challenge to CEOs and other community leaders to step up their giving."
More

Lilly cancels trials for experimental MS drug

July 28, 2009
J.K. Wall
Eli Lilly and Co. and a development partner has canceled clinical trials on an experimental drug to treat multiple sclerosis after the drug failed to delay progression of the disease in trial patients.
More

BREAKING: FDA approves Lilly blood-thinner prasugrel

July 10, 2009
J.K. Wall
Eli Lilly and Co. finally won approval today from U.S. regulators to sell prasugrel, its highly anticipated blood thinner, according to Bloomberg News.
More

Lilly cancer drug OK'd for new use

July 6, 2009
J.K. Wall
Eli Lilly and Co.'s top rising-star drug has been approved by U.S. regulators for a new use, an event that could boost sales of the medication. Alimta, a lung cancer drug, was approved as a maintenance therapy for non-small cell lung cancer for certain patients, Lilly announced today.
More

Lilly kicks lobbying into high gearRestricted Content

July 6, 2009
 IBJ Staff
Once again, Indianapolis-based Eli Lilly and Co. is running in the lead pack in dollars spent to bend ears on Capitol Hill. And that was even before the health care reform debate got rolling.
More

Peterson has passion for health care and new Lilly positionRestricted Content

June 29, 2009
J.K. Wall
A new communications post at Eli Lilly gives former mayor Bart Peterson an opportunity to meld his experiences in the public and private sectors.
More

VIEWPOINT: CEOs, do you deserve your salaries?Restricted Content

June 22, 2009
John Guy
An exaggerated share of the nation's wealth is paid to CEOs of public companies, their minions and directors, through agreements made inside boardrooms, by highly compensated individuals who commit shareholders' money and are not subject to effective oversight.
More

With Byetta's sales stalled, Lilly unveils its own competitorRestricted Content

June 15, 2009
 IBJ Staff
While Eli Lilly and Co. continues to work with a biotech firm on the diabetes medicine Byetta, it's developing a potential competitor to Byetta all on its own.
More

Lilly, Simon receive top philanthropic awardsRestricted Content

May 25, 2009
Two global companies based in Indianapolis have been recognized for their philanthropic efforts.
More

Keep Indianapolis Beautiful and Lilly team up on I-70 landscaping projectRestricted Content

May 18, 2009
Kathleen McLaughlin
Some of Indianapolis' main entrances from Interstate 70 are in line for a $2 million makeover.
More

With pharma famine looming, Lilly relying on snack-size dealsRestricted Content

May 4, 2009
J.K. Wall
Compared with some of his pharmaceutical CEO peers these days, John Lechleiter has his company on a diet. Instead of using a mega-merger to bulk up before the famine that patent expirations will bring on the industry next year, Lechleiter has Eli Lilly and Co. burning management fat while looking for smaller companies to munch on.
More
Page  << 21 22 23 24 >> pager
Sponsored by
ADVERTISEMENT

facebook - twitter on Facebook & Twitter

Follow on TwitterFollow IBJ on Facebook:
Follow on TwitterFollow IBJ's Tweets on these topics:
 
Subscribe to IBJ
  1. PJ - Mall operators like Simon, and most developers/ land owners, establish individual legal entities for each property to avoid having a problem location sink the ship, or simply structure the note to exclude anything but the property acting as collateral. Usually both. The big banks that lend are big boys that know the risks and aren't mad at Simon for forking over the deed and walking away.

  2. Do any of the East side residence think that Macy, JC Penny's and the other national tenants would have letft the mall if they were making money?? I have read several post about how Simon neglected the property but it sounds like the Eastsiders stopped shopping at the mall even when it was full with all of the national retailers that you want to come back to the mall. I used to work at the Dick's at Washington Square and I know for a fact it's the worst performing Dick's in the Indianapolis market. You better start shopping there before it closes also.

  3. How can any company that has the cash and other assets be allowed to simply foreclose and not pay the debt? Simon, pay the debt and sell the property yourself. Don't just stiff the bank with the loan and require them to find a buyer.

  4. If you only knew....

  5. The proposal is structured in such a way that a private company (who has competitors in the marketplace) has struck a deal to get "financing" through utility ratepayers via IPL. Competitors to BlueIndy are at disadvantage now. The story isn't "how green can we be" but how creative "financing" through captive ratepayers benefits a company whose proposal should sink or float in the competitive marketplace without customer funding. If it was a great idea there would be financing available. IBJ needs to be doing a story on the utility ratemaking piece of this (which is pretty complicated) but instead it suggests that folks are whining about paying for being green.

ADVERTISEMENT